These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29931506)

  • 21. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanisms and efficacy of SGLT2 inhibitors].
    Shiba T
    Nihon Rinsho; 2015 Mar; 73(3):438-46. PubMed ID: 25812370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
    Zou CY; Liu XK; Sang YQ; Wang B; Liang J
    Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.
    Chawla G; Chaudhary KK
    Diabetes Metab Syndr; 2019; 13(3):2001-2008. PubMed ID: 31235127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring.
    Torimoto K; Okada Y; Koikawa K; Tanaka Y
    Diabetol Metab Syndr; 2017; 9():60. PubMed ID: 28785316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin.
    Woo VC; Berard LD; Bajaj HS; Ekoé JM; Senior PA
    Can J Diabetes; 2018 Feb; 42(1):88-93. PubMed ID: 28579198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved glycemic control in mice lacking Sglt1 and Sglt2.
    Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
    Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
    Tahara A; Takasu T
    Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ohashi M; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Diabetes Ther; 2017 Oct; 8(5):999-1013. PubMed ID: 28864997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes.
    Sakamoto M; Goto Y; Nagayama A; Yano M; Sato S; Tajiri Y; Nomura M
    Diabetol Int; 2022 Jan; 13(1):117-123. PubMed ID: 35059247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
    Baruah MP; Makkar BM; Ghatnatti VB; Mandal K
    Indian J Endocrinol Metab; 2019; 23(1):140-149. PubMed ID: 31016169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
    Seufert J
    Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.